Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Antibody drug refers to the preparation of antibody engineering technology based on cell and genetic engineering technology. It has high specificity, effectiveness and safety in binding to the target antigen. It is clinically used for major diseases such as malignant tumors and autoimmune diseases.
The research and development of antibody drugs, from preclinical candidate compounds to CMC period, following by the clinical test of IND (investigational new drug), finally, completing the NDA (new drug application) declaration, basically, it will take years. Throughout the whole process of antibody drug discovery, the lead selection is the beginning of the story. It can be said that lead selection projects could be admired as the tickets for antibody drug discovery. CUSABIO has been committed to the development and production of proteins and antibodies, and can provide a one-stop service for your early discovery of antibody drugs and accelerate your whole development process.
CUSABIO has been specialized in the production of transmembrane protein for more than 13 years, so we are confident we can prepare the "right" antigen for the lead selection of antibody drug discovery. Mostly, CUSABIO has good experience in projects of lead selection, so we are sure we can meet the various demands of our customers under mutiple options of technology.
Contact us or leave a message: If you have any need and requirement, please feel free send any inquiry to [email protected]. Additionally, you can also leave message to us at the bottom of this page.
Positive antibody refers to drug control antibody. It is usually used to detect the antigen or stable cell line to determine whether the antigen or stable cell line is qualified. In addition, It also acts as a control to screen antibody in FACS. The priority order of positive antibody sequence reference is as follows: marketed antibody drugs, clinical stage (Ⅰ-Ⅲ) antibody drugs, preclinical stage antibody drugs, and FACS antibodies.
CUSABIO has 15 years of experience in recombinant protein expression and can provide one-stop services from gene synthesis, vector construction to protein expression and purification. Based on the traditional five recombinant protein expression systems (E. coli, Yeast, Insect Baculovirus, Mammalian cell and In vitro E.coli systems), CUSABIO has now launched four dominant protein expression platforms for drug target proteins, namely Virus-like Particles (VLPs), Detergent Micelle, Nanodisc and Nanoparticle platforms. More interesting reading related Virus-like Particles, Detergent Micelle, Nanodisc and Nanoparticle platforms>>
Stable cell line refers to a cell line that continuously and stably expresses or interferes with the expression of a specific gene through stable transduction. In the field of antibody development, stable transfected cell lines can be used as immunogens to stimulate specific immune responses in animals, and can target multiple transmembrane proteins. In addition, stable transfected cell lines are widely used in antibody binding and functional screening experiments. CUSABIO can provide stable cell line construction service, and the specific service contents are as follows:
| Lentivirus Packaging and Construction of Stable Cell Service | |||
| No. | Process | Service Items | Service Cycle |
|---|---|---|---|
| 1 | Construction of recombinant plasmid | Codon optimization, full gene synthesis, construction of lentiviral expression vector, large-scale extraction of plasmids | 2-3 weeks |
| 2 | Lentiviral packaging | Co-transform the expression vector and helper plasmid into 293T cells for lentivirus packaging | 1-2 weeks |
| 3 | Cell pool screening and verification | Screen the positive cells with the corresponding screening agent, and detect the expression level of the cell pool | 1-2 weeks |
| 4 | Monclonal stable cell screening and verification | Plate single cells and verify the expression of monclonal stable cell | 3-4 weeks |
| 5 | Monclonal stable cell cryopreservation and QC | Monclonal stable cell expansion culture, cryopreservation, resuscitation detection viability rate and microbial contamination | 1-2 weeks |
| Total time | 8-12 weeks | ||
CUSABIO can provide a variety of host species for immunization, to meet the different needs of different customers.
CUSABIO has 15 years of rich experience in the development of hybridoma monoclonal antibodies with mature technical routes, stable and reliable product quality and high success rate. The initial positive rate is as high as about 20%-40%, and the positive rate in FACS is about 10%-20%, which can meet the needs of different types of customers.
CUSABIO has qualified native and immunized phage display libraries with capacity of 1011, including alpaca native library, humanized nano library, human library, mouse library. The correct insertion rate of CUSABIO libraries can be as high as 100%, and the positive rate of screening can be above 90%. So we can provide rapid screening service, and finish the antibody screening within 2-4 weeks at the fastest as well, the antibody affinity can reach the level of nM. CUSABIO can offer the services of antibody humanization and affinity maturation to our customers.
CUSABIO is going to express the top postitive clones for fruther validation according to customers' requirement. CUSABIO can guarantee the produced antibody can be succeeded in FACS with stable cell lines.
